Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2009

View Archived Issues

Data on evaluation of rivastigmine clinical safety and efficacy disclosed at ICAD

Inovio reports results from animal studies of H1N1 influenza vaccines

Medicis and Revance sign license agreement for neurotoxin RT-002

Novel kinase inhibitors claimed by Bayer Schering Pharma for cancer

Cascade Therapeutics describes 5-HT2C receptor agonists for obesity and other diseases

Janssen discloses NPY Y2 antagonists for the treatment of alcoholism

AMPA glutamate receptor agonists in development at GSK for treatment of schizophrenia

Cascade Therapeutics presents novel compounds for the treatment of epilepsy

MSM and Merck Serono collaborate to create antibody-based products targeted to GPCRs

FDA accepts Roche's complete response resubmission of the Actemra BLA for RA

FDA advisory committee recommends Schering-Plough's Saphris for bipolar I disorder

GTAC issues favorable opinion on ReNeuron's phase I clinical trial of Re-N001 in stroke

Zogenix and Astellas sign exclusive U.S. copromotion agreement for Sumavel DosePro

ACT Biotech initiates treatment in phase II clinical trial of telatinib in gastric cancer

Repros suspends dosing of Proellex in clinical trials

Invega Sustenna approved for acute and maintenance schizophrenia treatment

FDA approves Livalo for primary hypercholesterolemia and dyslipidemia

Opioid antagonist naltrexone reduces stealing urges in adult kleptomaniacs

Cx-401 is safe and effective in the treatment of complex perianal fistulas in phase II trial

Placenta-derived adherent stromal cells, PLX, effective in animal model of limb ischemia

HCV vaccine IC-41 add-on therapy induces T-cell response but does not prevent relapse

Amgen reports top-line results for denosumab trial in bone metastases

The European Commission approves Otsuka's Samsca

Micromet receives European orphan drug designation for blinatumomab

Astellas to file an NDA in Japan for XP-13512 in RLS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...